Glutamate Neurotoxicity in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000010
Summary
Dr. Ayoub is exploring the role of the signaling molecule glutamate, acting through NMDA receptors, in retinal ganglion cell death. He has hypothesized that, under the high IOP conditions found in glaucoma, glutamate is released continuously. This would be an important finding if true because the prolonged presence of glutamate can be toxic to nerve cells and stimulate cell death. Dr. Ayoub is measuring glutamate and analyzing its effects on ganglion cell survival to determine the amount of glutamate that is sufficient to cause cell death. In addition, the neuroprotective action of cannabinoids is being analyzed to determine if they can suppress glutamate levels and/or suppress cell death. Dr. Ayoub has already determined the level of glutamate needed to cause neurotoxicity, and has refined his experimental approach accordingly. Clinical trials are now taking place elsewhere to determine the effects of glutamate suppressors in glaucoma, so the results of this study could prove timely.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine